Snapshot from Jul 19, 2026 at 14:14 UTC. For live data and tracking: View Live
Events / Business / Can-Fite Namodenoson Pancreatic Cancer Study
Business clinical trial results

Can-Fite Namodenoson Pancreatic Cancer Study

Analysis based on 6 articles · First reported Jul 01, 2026 · Last updated Jul 01, 2026

Sentiment
60
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The positive Phase 2a results for Namodenoson in pancreatic cancer are expected to positively impact the stock price and investor confidence in Can-Fite BioPharma Ltd. The decision to advance Namodenoson to a Phase 2b combination study with chemotherapy suggests a stronger pipeline and potential for future revenue, attracting more investment in the biotechnology sector.

Biotechnology Pharmaceuticals
Event Summary

Can-Fite BioPharma Ltd. announced positive results from its Phase 2a study of Namodenoson in patients with advanced pancreatic ductal adenocarcinoma. The study achieved its primary safety endpoint and demonstrated durable overall survival outcomes, particularly in heavily pretreated patients. One patient receiving Namodenoson as second-line therapy remains alive for over 18 months. Based on these findings and preclinical data showing Namodenoson's ability to enhance chemotherapy activity, Can-Fite BioPharma Ltd. plans to advance Namodenoson into a Phase 2b combination study with chemotherapy. Prof. Salomon Stemmer, the study lead, endorsed further investigation of Namodenoson.

Key Actions
100 Can-Fite BioPharma announced results
90 Can-Fite BioPharma plans to advance Namodenoson
Entities Involved
stock
Can-Fite BioPharma
Can-Fite BioPharma Ltd. announced positive Phase 2a study results for Namodenoson in pancreatic cancer, which supports further clinical development and plans for a Phase 2b combination study, potentially increasing its market value and drug pipeline strength.
Importance 100.0 Sentiment 70.0
oth
Namodenoson
Namodenoson, a drug developed by Can-Fite BioPharma Ltd., showed durable survival outcomes and a favorable safety profile in a Phase 2a study for advanced pancreatic cancer, leading to plans for further clinical development in combination with chemotherapy.
Importance 95.0 Sentiment 65.0
per
Salomon Stemmer
Prof. Salomon Stemmer, the lead investigator of the Phase 2a study, provided expert commentary supporting the promising results of Namodenoson and recommended its further evaluation in combination with chemotherapy.
Importance 40.0 Sentiment 50.0
oth
Davidoff Institute of Oncology
The Davidoff Institute of Oncology, Rabin Medical Center, Israel, is where Prof. Salomon Stemmer, the lead investigator, is a professor.
Importance 10.0 Sentiment 0.0
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration previously granted Namodenoson Orphan Drug Designation and Fast Track Designation for hepatocellular carcinoma, indicating its potential regulatory path.
Importance 10.0 Sentiment 0.0
cnt
Israel
Israel is the location of Can-Fite BioPharma Ltd. and the Davidoff Institute of Oncology, Rabin Medical Center, where the study lead is based.
Importance 5.0 Sentiment 0.0
Relationships
United States — Food and Drug Administration related ↔ Israel
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.